Delta Wave Sleep Promotion
Promotes delta wave (slow-wave) sleep activity in animal and human studies. The peptide deepens existing sleep architecture rather than sedating.
[3]A nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit cerebral venous blood after electrical stimulation of thalamic sleep centers. DSIP promotes delta wave (deep, slow-wave) sleep and has been investigated for stress modulation, withdrawal syndromes, chronic pain, and HPA axis regulation.
At a glance
- Type
- Nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)
- Origin
- Isolated from rabbit cerebral venous blood after electrical stimulation of thalamic sleep centers
- Route
- Subcutaneous, 30 to 60 minutes before bedtime
- Status
- Investigational; large RCT evidence does not exist in Western literature
- Interactions
- Theoretical interaction with benzodiazepines, opioids, and other CNS depressants
What the research supports
DSIP's evidence base spans deep sleep promotion, stress hormone modulation, withdrawal applications, and recent fusion peptide work that improves CNS delivery.
HPA Axis and Stress Modulation
Reduces stress-induced hyperarousal, modulates corticosteroid and ACTH secretion, and supports HPA axis balance and circadian normalization.
[4]BBB-Penetrating Fusion Peptide
A DSIP fused to a blood-brain barrier penetrating sequence improved sleep in a PCPA-induced insomnia mouse model, with effects on serotonin, glutamate, dopamine, and melatonin.
[1]Orthopedic Recovery Review
Reviewed alongside other recovery-enhancing peptides targeting circadian and mitochondrial regulators in orthopedic literature.
[2]Summary of key findings
Deep Sleep Specificity
DSIP targets delta wave sleep, the most restorative phase and the one most commonly impaired in aging and chronic stress.
Not a Sedative
The peptide deepens existing sleep architecture rather than producing pharmacological sedation. No dependence or rebound documented.
Stress and HPA Modulation
Beyond sleep, DSIP modulates corticosteroid and ACTH secretion and supports stress recovery.
Investigational Status
Mechanism is plausible and safety is favorable, but large RCT evidence does not exist in Western literature. Framing should be appropriately conservative.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Pre-Bedtime Protocol
- 100 to 300 mcg subcutaneous, 30 to 60 minutes before bedtime.
- Cycling
- Most protocols run 4 to 8 week courses with breaks of at least 2 weeks. Intermittent as-needed use is also reported.
- Combination Approach
- Often combined with sleep hygiene optimization, melatonin, and other sleep supports rather than used as monotherapy.
- Caution with CNS Depressants
- Theoretical interaction with benzodiazepines, opioids, and other CNS depressants. Combine with caution.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| DSIP 5 mg / 1 mL | 100 to 300 mcg | 2 to 6 units | Nightly, ongoing as needed | 0.05 mg per unit. PM empty stomach, 60 to 90 minutes after last meal. |
| DSIP 10 mg / 1 mL | 100 to 300 mcg | 1 to 3 units | Nightly, ongoing as needed | 0.1 mg per unit. PM empty stomach, 60 to 90 minutes after last meal. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
DSIP is one of the cleanest sleep-supporting peptides available. The mechanism specifically targets delta wave sleep, the most restorative phase. Position it for patients with poor sleep quality rather than just sleep onset issues.
It is not a substitute for sleep hygiene. Any DSIP protocol should be paired with consistent bedtime, light exposure management, and stress management. Pairs well with Epitalon for combined sleep and longevity protocols, and with magnesium glycinate and apigenin in functional sleep stacks.
Stress and HPA applications are underused. Patients with high evening cortisol may benefit more than pure sleep maintenance complaints.
Deep Sleep Support
Targets delta wave sleep, the most restorative phase
Stress Modulation
Normalizes HPA axis activity and stress hormone secretion
Withdrawal Adjunct
Investigational use in opioid and alcohol withdrawal protocols
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Mu et al., 2024 DSIP Fusion Peptide Efficacy in PCPA-Induced Insomnia
- 2Rahman et al., 2026 Therapeutic Peptides in Orthopaedics Review Including DSIP
- 3DSIP and Slow-Wave Sleep Regulation ReviewCitation under review
- 4DSIP Modulation of HPA Axis and Stress Hormone SecretionCitation under review
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.